Search Bar & Filters
Found 11 Actively Recruiting clinical trials
Actively Recruiting
Researchers are collecting clinical data to evaluate the ongoing safety and performance of commercially approved Biosense Webster Inc. BWI medical devices used during routine cardiac arrhythmia mapping and ablation procedures. This observational study aims to confirm the safety and effectiveness of these devices in real-world settings and expand knowledge about their use in treating cardiac arrhythmias such as atrial fibrillation, supraventricular tachycardia, and ventricular tachycardia. Participants diagnosed with cardiac arrhythmias who are scheduled for catheter ablation using BWI therapeutic catheters, including Varipulse Catheter and Dual Energy THERMOCOOL SMARTTOUCH SF Catheter, will be observed during their routine clinical care. No specific interventions are assigned by the study instead, participants undergo standard treatment with these devices as part of their medical management. During the study, participants will be monitored for adverse events related to the devices and procedures, both shortly after ablation and up to one year. Researchers will track arrhythmia outcomes and repeated procedures as part of routine follow-up. Data collection includes safety assessments, arrhythmia recurrence, and hospitalization events. Participation may last up to a year, with ongoing observation during routine healthcare visits.
Actively Recruiting
This research focuses on patients who have experienced ST segment elevation myocardial infarction STEMI and require percutaneous coronary intervention PCI. The study compares two approaches a shorter duration of dual antiplatelet therapy DAPT with Prasugrel followed by Prasugrel monotherapy versus the standard one-year DAPT regimen. Additionally, in patients with multivessel disease MVD, the trial evaluates the effectiveness and safety of complete revascularization guided by either Optical Coherence Tomography OCT or angiography. Participants receive a loading dose of aspirin and Prasugrel at the time of PCI, treating the culprit lesion first. For those with MVD, non-culprit lesions are treated in staged procedures within 15 days. Following 30 to 45 days after the initial procedure, eligible patients are randomized to either continue short DAPT with Prasugrel monotherapy or follow the standard 12-month DAPT. Complete revascularization in MVD patients is further randomized to OCT-guided or angiography-guided strategies. Participants will be followed clinically for 35 months after randomization to monitor outcomes, with key assessments at 11 and 35 months. Researchers will measure safety and efficacy endpoints, including major adverse cardiac and cerebrovascular events and bleeding events. The study includes detailed monitoring of treatment adherence, successful revascularization, and clinical events to evaluate the comparative benefits of the treatment strategies.
Actively Recruiting
Researchers are evaluating maridebart cafraglutide as an additional treatment to standard care to reduce heart failure events, cardiovascular deaths, and improve symptoms in adults with heart failure who have preserved or mildly reduced ejection fraction and obesity. This phase 3 global trial includes a double-blind period followed by an open-label extension. The study will continue until approximately 850 primary endpoint events have occurred, focusing on serious heart failure outcomes. Participants will be randomly assigned to receive either maridebart cafraglutide or a placebo, both given by subcutaneous injection. The trial includes two parts an initial double-blind phase where neither participants nor researchers know the assigned treatment, followed by an open-label extension where all participants may receive the active drug. This design helps assess the drugs impact on heart failure and related cardiovascular events. During the study, participants will undergo regular assessments including questionnaires to measure heart failure symptoms and quality of life, blood tests for kidney function, blood sugar, cholesterol, and inflammation markers, as well as monitoring of heart failure events and mortality. The main outcome is the time until cardiovascular death or heart failure events over about 35 months. Safety and other health measures will also be tracked throughout the trial, which lasts up to about three years.
Actively Recruiting
Researchers are evaluating the impact of implantable cardioverter-defibrillators ICDs on patients who have survived a myocardial infarction heart attack and have a severely reduced left ventricular ejection fraction LVEF of 35% or less. This group is at increased risk of sudden cardiac death caused by dangerous heart rhythms. Past landmark trials showed ICDs improved survival, but advances in medical therapy have changed patient outcomes, prompting the need to reassess the benefits and risks of ICDs alongside current optimal treatments. In this randomized trial, participants receive optimal medical therapy OMT based on European Society of Cardiology guidelines for managing heart failure and chronic coronary syndromes. One group will also receive an ICD device, while the other group will not. The study compares outcomes between these two groups to determine if OMT without ICD is not worse than OMT with ICD in preventing death. The trial includes patients with symptomatic heart failure and reduced LVEF after a myocardial infarction. Participants will be followed over time with regular evaluations to monitor health and outcomes. Researchers will measure the time from randomization to death from any cause as the primary outcome, with additional assessments including cardiovascular death, sudden cardiac death, hospital readmissions, length of hospital stays, and quality of life over a year. The study is event-driven and expects to observe outcomes about 15 months after the last participant is enrolled. Safety and effectiveness of treatments will be carefully monitored throughout.
Actively Recruiting
Researchers are monitoring the clinical performance and short-term safety of Resorbable Magnesium Scaffolds RMS used in patients with symptomatic coronary artery disease. This registry follows the ESCEACTS guideline and observes RMS use in real-world settings without additional medical exclusion criteria beyond the devices intended instructions for use. The devices studied include Magmaris and Freesolve, both designed to improve the luminal diameter in the treatment of new native coronary artery lesions. The scaffold size is matched to the vessel diameter, and lesion length is limited to the scaffold length. The study collects data on these devices as they are used according to their approved instructions. Participants will be followed to assess the primary outcome of Target Lesion Failure within 12 months after device implantation. The registry collects clinical information during routine care to evaluate device performance and safety over time. The study started in November 2020 and will continue through May 2030.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of the Orsiro Mission 48-mm Sirolimus-Eluting Coronary Stent System in people with coronary artery disease who have atherosclerotic lesions longer than 36 mm and up to 44 mm in their native coronary arteries. The study focuses on lesions with a reference vessel diameter between 2.25 mm and 4.0 mm. This is a prospective, multicenter, single-arm study sponsored by Teleflex, aiming to treat subjects with these specific lesions using this device. Participants will receive the Orsiro Mission stent, which consists of a cobalt chromium stent platform coated with a bioabsorbable polymer containing the drug sirolimus. This device is designed to be implanted in the coronary arteries during percutaneous coronary intervention PCI. The study involves a single group receiving this stent to assess its performance in treating lesions of the specified length and size. During the study, participants will have follow-up visits to monitor outcomes and safety. Those enrolled in the United States will be followed for 2 years with visits at 1, 6, 12 months, and 2 years after the procedure. Participants outside the United States will be followed for 5 years with additional visits at 3 and 5 years. Researchers will measure target lesion failure at 12 months as the primary outcome and will also track device and procedure success, deaths, heart attacks, major cardiac events, revascularizations, and stent thrombosis throughout the follow-up period.
Actively Recruiting
Coronary artery disease occurs when the arteries narrow, sometimes requiring a procedure called Percutaneous Coronary Intervention PCI to open them. This study focuses on treating calcified coronary artery lesions, which can make stent placement difficult. Researchers are comparing two devices that use sonic pressure waves to break up calcified plaques the newer ShockFast IVL and the more established Shockwave IVL. The trial aims to assess how these devices perform in treating these challenging lesions. Participants receive treatment with one of two devices during PCI. The ShockFast IVL device uses sonic pressure waves to safely fracture calcium deposits, aiming to keep the artery flexible and allow smoother stent placement. It offers an improved crossing profile and two catheter lengths. The Shockwave IVL device also uses sonic pressure waves but has only one catheter length. Both devices are used during the coronary intervention procedure to modify calcified plaques. During the study, participants undergo PCI with one of the two devices. Researchers measure the stent area at the narrowest artery point during the procedure using optical coherence tomography OCT. Additional outcomes include target lesion failure, angiographic success, and device success assessed up to 30 days after the procedure. The study involves hospital assessments during the procedure and follow-up visits over 30 days to monitor safety and effectiveness. The trial is expected to complete by March 2027.
Actively Recruiting
This research focuses on patients with coronary chronic total occlusions undergoing recanalization procedures. It is a prospective registry conducted at the Heart Center in Bad Segeberg, Germany, tracking patients treated for these heart artery blockages. The study aims to observe outcomes over time, including complications and cardiovascular events. Participants undergo percutaneous transluminal angioplasty using dedicated drug-eluting stents andor balloons as part of their treatment for coronary chronic total occlusions. The registry records details of these procedures and the patients receiving them, without randomization or comparison groups. The study collects data throughout routine clinical care and follow-up visits. During the study, patients will be monitored for in-hospital and long-term cardiovascular adverse events, with follow-up extending up to at least two years. The study involves regular clinical assessments and data collection to evaluate the safety and outcomes of the recanalization procedures. Participation continues with standard medical care and long-term observation at the center.
Actively Recruiting
This research aims to follow patients with severe mitral regurgitation MR who are treated using a procedure called mitral edge-to-edge repair M-TEER. The study is conducted at a single center, the Heart Center in Bad Segeberg, Germany, and focuses on observing patients undergoing this treatment to understand their health outcomes over time. Participants receive the mitral valve transcatheter edge-to-edge repair M-TEER, a device-based procedure designed to address severe MR. The study records data from patients treated with this procedure and follows them through a routine clinical schedule, including long-term follow-up to monitor their condition and treatment effects. Throughout the study, participants undergo regular clinical assessments, with researchers tracking their health status and any cardiovascular adverse events that occur both during hospitalization and over a two-year period. The main outcome measured is the rate of these adverse events. Participants are monitored closely according to the study protocol, which extends over a long-term timeline to gather comprehensive follow-up information.
Actively Recruiting
This observational study follows patients with coronary artery disease who undergo rotational atherectomy for coronary lesions at the Heart Center in Bad Segeberg, Germany. It aims to collect long-term data on cardiovascular outcomes after this procedure as part of routine clinical care, providing insights into patient experiences and health over time. Patients receive rotational atherectomy as part of their coronary artery disease treatment. The study includes all patients undergoing this procedure and follows them with a routine clinical follow-up schedule. The study is conducted at a single center and involves no experimental treatment or placebo. Participants are monitored through standard clinical visits over a long-term period, with researchers tracking the rate of in-hospital and long-term cardiovascular adverse events within two years. This data will help evaluate the safety and outcomes of rotational atherectomy in everyday clinical practice. The total participation time varies based on the follow-up schedule.
1-10 of 11
1